99.73  3.49 (3.63%)		12-19 16:00
Open: 96.79 High: 102.4497 Volume: 915,521		Pre. Close: 96.24 Low: 95.96 Market Cap: 1,180(M)

Short term
Mid term
Targets	6-month :	130.81	1-year :	152.79
Resists	First :	112	Second :	130.81
Pivot price	95.87
Supports	First :	91.59	Second :	78.98
MAs	MA(5) :	94.64	MA(20) :	96.39
	MA(100) :	69.45	MA(250) :	0
MACD	MACD :	3.2	Signal :	4
%K %D	K(14,3) :	38.6	D(3) :	32.8
RSI	RSI(14): 57.5
52-week	High :	112	Low :	11.89

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ PVLA ] has closed below upper band by 23.1%. Bollinger Bands are 5.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	102.58 - 103	103 - 103.39
Low:	94.97 - 95.41	95.41 - 95.83
Close:	99.01 - 99.72	99.72 - 100.39

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

Fri, 19 Dec 2025
Palvella Therapeutics (NASDAQ:PVLA) COO Kathleen Goin Sells 4,302 Shares - MarketBeat

Thu, 18 Dec 2025
Assessing Palvella Therapeutics After Its 666.8% Surge and Late Stage Pipeline Progress - simplywall.st

Thu, 18 Dec 2025
FY2026 EPS Estimates for PVLA Decreased by Lifesci Capital - MarketBeat

Wed, 17 Dec 2025
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Palvella Therapeutics (PVLA) - The Globe and Mail

Tue, 16 Dec 2025
Chardan Capital Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq

Tue, 16 Dec 2025
Palvella Therapeutics (NASDAQ:PVLA) Trading Up 6.6% on Analyst Upgrade - MarketBeat

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	12 (M)
Shares Float	7 (M)
Held by Insiders	21.3 (%)
Held by Institutions	73.8 (%)
Shares Short	835 (K)
Shares Short P.Month	752 (K)

EPS	-2.93
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.49
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-47.6 %
Return on Equity (ttm)	-301.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-25 (M)
Levered Free Cash Flow	-17 (M)

PE Ratio	-34.16
PEG Ratio	0
Price to Book value	28.57
Price to Sales	0
Price to Cash Flow	-46.37

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.